Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Phase 3 trial of elafibranor in PBC with inadequate response or intolerance to UDCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elafibranor received accelerated approval in 2024 as a second-line therapy for adults with PBC who have an inadequate response or intolerance to UDCA, based on results from the phase 3 ELATIVE trial demonstrating significant biochemical response and favorable tolerability, including no worsening of pruritus [50,51].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“On the other hand, seladelpar (PPAR-δ selective) consistently improves pruritus and shows high biochemical response rates, while elafibranor (dual PPAR-α/δ) improves biochemical endpoints with a neutral pruritus effect but a reassuring safety signal overall [16,50].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“Among patients with moderate-to-severe pruritus (44 in the elafibranor group and 22 in the placebo group), the least-squares mean change in WI-NRS score from baseline through week 52 did not differ significantly between the two groups.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“However, fibrosis-related endpoints such as transient elastography and non-invasive fibrosis scores were neutral in this trial.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“Normalization of ALP levels at week 52 occurred in 15% of patients receiving elafibranor and in none of the patients receiving placebo (p < 0.002) [50].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Self-citationIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationThe 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Self-citation
Cited by
Items 201–300 of 305
Kommentar zu: PPAR-Agonist bei primär biliärer Cholangitis wirksam
Herta, T., & Tacke, F. (2024) · Gastroenterologie up2date · doi:10.1055/a-2410-4180
Primary biliary cholangitis, a rising health burden
Elnaggar, M., Elkhattib, I., Abomhya, A., & Boyer, J. L. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00165 · Cited by 1
Zhou, H., Yang, J., Wu, W., Wei, S., ZHAO, Y., & Li, C. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2695704
AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update
Aghemo, A., Calvaruso, V., Carbone, M., Cazzagon, N., Cristoferi, L., D’Amato, D., D’Ambrosio, R., Fianchi, F., Germani, G., Giannini, E. G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.06.019 · Cited by 3
Self-citationQualitative Evaluation of Fatigue and Pruritus Among Patients with Primary Biliary Cholangitis
Levy, C., Williams, B., Sowell, F. G., Dietrich, J., Boing, E., Wright, G., & Schattenberg, J. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03691-4 · Cited by 1
Self-citationNeue Standards in der Behandlung der primären biliären Cholangitis
Vögelin, M., & Kremer, A. E. (2025) · Schweizer Gastroenterologie · doi:10.1007/s43472-025-00173-w
Medikamentöse Therapie der Leberzirrhose
Schachteli, F., Uschner, F. E., Trebicka, J., & Brol, M. J. (2026) · Gastroenterologie up2date · doi:10.1055/a-2358-8821
Zhang, J., Xu, J., Bao, W., & Tang, Y. (2026) · Gastroenterology Research and Practice · doi:10.1155/grp/8688776
Diagnostik und Therapie der Grunderkrankung bei Leberzirrhose
Lang‐Meli, J., & Neumann‐Haefelin, C. (2025) · Springer eBooks · doi:10.1007/978-3-662-70167-6_11
Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis
Halilbasic, E., Tatscher, E., Aigner, E., Burghart, L., Graziadei, I. W., Hametner‐Schreil, S., Hofer, B., Hofer, H., Maieron, A., Mandorfer, M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02798-6
Elafibranor y seladelpar en colangitis biliar primaria
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.486.5
Primary biliary cholangitis review – new management strategies emerge
Gatley, E., Gogela, N. A., & Sonderup, M. W. (2025) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.2491
Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit
Yan, S., Wang, H., Du, S., Li, Y., Yang, D., Xu, M., & Jin, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1766177
Berikkhanov, Z. G. M., Akulov, Z. A., Emtsev, M. A., Tarabrin, E. А., Shestakov, A., Kotelnikov, A., Nikolaev, A., Razumovsky, V. S., Ivanova, M. Y., Ebrahimnezhad, M., et al. (2026) · Metabolites · doi:10.3390/metabo16100721
Autoimmune Lebererkrankungen diagnostizieren und behandeln
Sebode, M. (2025) · Gastro-News · doi:10.1007/s15036-025-3947-1
Primär biliäre Cholangitis – Update zu Diagnostik, Risikostratifizierung und neuen Therapieoptionen
Herta, T., & Berg, T. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01988-0
10. Advances in the Management of Intractable Hepato-biliary Diseases
Tanaka, A. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1748
Immunomodulatory mechanisms of bile acids in autoimmune diseases along the gut-liver axis
Zhang, S., Xiong, X., Wei, S., Meng, R., An, H., & Chen, L. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104183 · Cited by 1
Ren, W., Zhang, C., Wang, H., Song, H., Zhu, X., Zhang, Z., Zhao, S., & Wang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1674693
Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Sandhu, S., & Goel, A. (2026) · Seminars in Liver Disease · doi:10.1055/a-2952-2261
MASLD In PBC : A Shift From Liver‐Centred to Cardiometabolic Risk Assessment?
Colapietro, F., & Viganò, M. (2026) · Liver International · doi:10.1111/liv.70817 · Cited by 1
Steinmann, S., & Schramm, C. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01674-7
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Álvares‐da‐Silva, M. R., Andreoné, P., Arrese, M. A., Corpechot, C., Elbeshbeshy, H. A., Francque, S., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.016 · Cited by 1
Self-citationSanai, F. M., Alghamdi, A. S., Khathlan, A. A., Qutub, A. A., Quraishi, H. A., Alghamdi, M., ALZaabi, M. E. H., Mawardi, M., Altarrah, M. Y., Alnahdi, N., et al. (2026) · Cureus · doi:10.7759/cureus.113526
Prospects of elafibranor in treating alcohol-associated liver diseases
Cui, W.-T., Xue, H.-R., Wei, D.-F., Feng, X.-Y., & Wang, K. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i2.99549
Thakkar, H. H., Mathew, N. V., Reddy, E. P., Cheetiyar, A. L., Kommalapati, V., Mathew, A., Rajendiran, A., Riyaz, R., Joseph, N., Obadi, A. H., et al. (2025) · Cureus · doi:10.7759/cureus.82008 · Cited by 3
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Pharmacology of pruritus (pathophysiology, therapeutic targets)
Brenaut, E., & Misery, L. (2026) · Therapies · doi:10.1016/j.therap.2026.06.001
The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex
Nguyen, H. H., & Swain, M. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.001
Self-citationChung, A. H.-L., Tan, J. J.-R., Yap, R. X. J., Loo, J. H., Tay, W. X., Singh, C. L., Ong, S. J., Low, A. Y. J., Lin, Y., Lytvyak, E., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000940 · Cited by 1
Franke, A., Müller, T., Stein, K., Bantel, H., Günther, R., & Wiegand, J. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102254
Fan, Z., Jia, S., Wei, Y., Fan, X., Li, X., & Wang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845113
PPAR-Agonisten - etablierte Substanzen und neue Entwicklungen
Herta, T., & Tacke, F. (2025) · Gastro-News · doi:10.1007/s15036-025-3896-8
Xiong, J., Zhang, Z., Zhang, Z., Yuan, M., Zhu, K., Wang, F., & Shi, L. (2026) · eGastroenterology · doi:10.1136/egastro-2026-100526
Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective
Strasser, S. I., Thompson, A. J. V., Gupta, R., Lubel, J. S., French, J., Sacks, B., & Weltman, M. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70616
Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective
Bowlus, C. L., Bittencourt, P. L., Bobat, B., Gulamhusein, A. F., Kowdley, K. V., Levy, C., Lleo, A., Ma, X., & Tanaka, A. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004054 · Cited by 2
Self-citationDietary flavonoids target the gut–liver axis for the management of cholestatic liver injury
白冬松, Fan, S.-Q., Mu, Y., Zheng, D., Huang, X., Ma, H., & Li, L. (2026) · Food & Function · doi:10.1039/d6fo03181a
Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis
Zhao, W., Wu, Z., Kou, Q., Qiao, S., Liu, Z., & Zhang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1859342
Mohsen, M., Karkra, R., Medina‐Morales, E., Pagán-Busigó, J. E., Shamsian, E., Bebawy, M., Paracha, S., Patel, C., Sutariya, R., & Gaglio, P. J. (2026) · Livers · doi:10.3390/livers6020020
Zhong, M.-Y., Yang, S.-Y., Xu, W.-H., Zhang, Y.-K., & Zhao, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00544-y
Johnson, E. E., Orozco-Leal, G., Al-Assaf, A. S., Wu, H., Agbeleye, O., Hosseini-Jebeli, S., Sotire, T., Dobson, E., Wallace, S. A., Pearson, F., et al. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01525-9
Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States
Kumar, S., Shamseddine, N., Yang, H., Zhang, S., Ye, D., Seshasayee, S. M., Chen, J., & Kowdley, K. V. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03439-6
Self-citationFernández‐Rodríguez, C., García, M. L. G., & Olveira, A. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18048
Wang, X., Chen, J., Huo, B., Lin, W., Jiang, D.-S., Cheng, W., Zhao, F., & Gong, F. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178950
Berg, T., Trauner, M., & Trivedi, P. J. (2025) · EMJ Hepatology · doi:10.33590/emjhepatol/tnom7344
Primary Biliary Cholangitis: The Evolving Therapeutic Landscape
Schonfeld, E. A., & Kumar, S. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00741-x
Silveira, I. B., SÜFFERT, L. C., Leite, G. A. P. D., Tomé, M. R., de Lima, S. Q. L., Leite, G. A. P. D., Moraes, B. D. F., Passos, P. R. C., & Cançado, G. G. L. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70915
New therapies for primary biliary cholangitis usher in a personalised approach to treatment
France, N. L. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01129-x
Jayasekera, C. R., Barnhill, M. S., Chascsa, D. M. H., Croome, K. P., Carey, E. J., & Vargas, H. E. (2025) · Clinical Transplantation · doi:10.1111/ctr.70180
Liu, Y., Gong, S., Luo, X., Hu, Y., Yan, Q., Yang, Z., Mohsin, A., Zheng, S., & Guo, M. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174376
Safety profile of elafibranor versus placebo in primary biliary cholangitis
Khan, N. A., Shahbaz, H., Talha, M., Khan, M. A., Tahir, M. A., Anwar, U., Khan, M. S., & Adhikari, P. (2026) · Medicine · doi:10.1097/md.0000000000051009
Delphi consensus in primary biliary cholangitis: Collective introspection to set a path forward
Assis, D. N. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.07.010
Beres, R. L., Setchell, K. D. R., Mouzaki, M., & Zhao, X. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16070391 · Cited by 1
Faria, H. S., Sobral, M. V. S., Soares, V. G., Cavalheiro, T. T., Nishimoto, B., Pirolla, R. D. C., Sampaio, A. P., Gonçalves, O. R., COSTA, D. G. D., & Souto, E. B. (2024) · Research Square · doi:10.21203/rs.3.rs-4369688/v1
Ooi, Q. X., Brendel, K., van Beek, S. W., Zdovc, J. A., Bardol, M., & Dehez, M. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70247 · Cited by 1
American Association for the Study of Liver Diseases, & EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (2026) · Hepatology · doi:10.1097/hep.0000000000001791
Su, S., Yang, J., Luo, J., Yang, C., Li, C., Liu, X., Guo, G., & Han, Y. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02154-8
Romeo, M., Basile, C., Imperatore, A., Mozzi, G., Nardo, F. D., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2026) · Cells · doi:10.3390/cells15141292 · Cited by 2
Epidemiology, Pathogenesis and Treatment Progress of Primary Biliary Cholangitis
余, 兴. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153599
Systemischer Pruritus: hämatologische, nephrogene und hepatobiliäre Ursachen im Fokus
Koschmieder, S., Brand, M., & Kremer, A. E. (2026) · Die Dermatologie · doi:10.1007/s00105-026-05722-1
Jain, R., Kaur, G., Grover, P., Yasin, Z., & Singh, B. (2026) · Livers · doi:10.3390/livers6040077
Younossi, Z. M., Papatheodoridis, G., Tsochatzis, E. A., Buti, M., Rimassa, L., Pinzani, M., Lleò, A., Shawcross, D. L., Tacke, F., Wong, V. W., et al. (2026) · Liver International · doi:10.1111/liv.70806 · Cited by 2
Self-citationLiebe, R., Lammert, F., Schmidt, H. H., & Krawczyk, M. J. (2026) · Gut · doi:10.1136/gutjnl-2025-337027
Nguyen, H. H., & Swain, M. G. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70659
Self-citationThe emerging role of PPARs in primary biliary cholangitis
Palomer, X., Rodríguez‐Calvo, R., Mateo, S. G., Wahli, W., & Vázquez‐Carrera, M. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.05.008
Nuruzade, N., Oruc, U., Konstantis, G., Passenberg, M., Moghadam, A. D., Best, J., Veltkamp, C., Seltsam, F., Schmidt, H., Willuweit, K., et al. (2026) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848261492853
Kumar, S., Shamseddine, N., Yang, H., Zhang, S., Chen, J., & Kowdley, K. V. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0179
Self-citationBezafibrate for primary biliary cholangitis: A number needed to treat analysis
Werner, E., van de Vrie, M. A., van Hooff, M. C., Hansen, B. E., van der Meer, A. J., Abraham, S., Adang, R. P. R., Aktas, H., Alderlieste, Y. A., Aparicio-Pages, M. N., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101926
Romero‐Cristóbal, M. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2026.502720
Iqirvo for primary biliary cholangitis – efficacy, safety, and future directions
Saleem, R., Shakeel, A., Riaz, R., Noman, F., & Nasser, N. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003183 · Cited by 1
Ronconi, G., Dondi, L., Ambrosio, N., Calabria, S., Maverna, G., Acciai, V., Buttiglione, V., Invernizzi, P., Gentilucci, U. V., Carbone, M., et al. (2026) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2026.3767
Self-citationPemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
Tanigawa, R., Ueno, Y., Takahashi, H., Saito, A., Suganami, H., & Tanaka, A. (2026) · Hepatology Research · doi:10.1111/hepr.70244 · Cited by 1
Takeuchi, A., Komori, A., Kawata, K., Yoshida, O., Tanaka, A., Abe, K., Fujinaga, Y., Namisaki, T., Kimura, N., Katsumi, T., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70246
Sebode, M., & Lohse, A. W. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01028-9
Choi, Y., Schwab, A. J., Lim, J., Carlisle, S. M., McWherter, C. A., & Johnson, J. D. (2026) · PPAR Research · doi:10.1155/ppar/2362528
Kommentar zu: Primär biliäre Cholangitis: Elafibranor durchläuft erfolgreich Phase-III-Prüfung
Sebode, M. (2024) · Gastroenterologie up2date · doi:10.1055/a-2410-4314
Romero‐Cristóbal, M. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502720
Hogerty, C., Zhao, Y., Wang, W., Weinman, S. A., & Zhong, W. (2026) · Biomolecules · doi:10.3390/biom16060895
Qasim, B., Kumari, H., Kashif, S. N., Abbas, S. M. I., Hani, O., Salma, O., Sauleh, A., Adnan, F., Ali, M., Raheem, A., et al. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00464-6
Gish, R. G., Mendler, M. H., Mena, E., Kim, C., Perez, C. F. M., Pan, Y., Do, L., Samnaliev, M., & Agapova, M. (2026) · Liver international communications. · doi:10.1002/lci2.70044
Advances in Management Strategies for Primary Biliary Cholangitis
Rojas-Amaris, N., Marenco‐Flores, A., Barba, R., Mendoza, R., Patwardhan, V. R., & Bonder, A. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00700-y
Bolis, F., & Carbone, M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.003
Hayes, C. M., Cross, D. R., Achour, B., & Ghonem, N. S. (2026) · Cells · doi:10.3390/cells15161442
Silveira, I. B., Moraes, B. D. F., Rezende, R. A. A., & Cançado, G. G. L. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003108
Can we cure primary biliary cholangitis?
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102786
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Pediatric Cholestatic Liver Disease: A Contemporary Review of Etiology, Diagnostics, and Management
Vather, M., Lee, J., & Vittorio, J. (2026) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-026-00386-4
BAKULIN, I., & Mirtskhulava, V. V. (2026) · Медицинский вестник МВД · doi:10.52341/20738080_2026_143_4_28
Khamis, F., Teoh, E.-S., & Chan, W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-184 · Cited by 1
Gish, R. G., Mendler, M. H., Mena, E., Kim, C., Perez, C., Pan, Y., Samnaliev, M., Ito, D., & Agapova, M. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2595885
Nesbitt, G., & Curley, A. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261427491
New therapies for primary biliary cholangitis
Sohal, A., Alamgir, M., & Kowdley, K. V. (2026) · Hepatology International · doi:10.1007/s12072-026-11088-2
Self-citationNuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Guri, Y., & Kremer, A. E. (2024) · Schweizer Gastroenterologie · doi:10.1007/s43472-024-00132-x
王, 红. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641476
A decade of progress in cholestatic liver diseases: navigating a new era
Ronca, V., Maria, B., & Lleò, A. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00045-2
General Hepatology Concerns for the Patient with Cholestatic Liver Disease
Deeb, M., & Ma, M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.007
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
Tatscher, E., Mady, S., & Fickert, P. (2025) · Seminars in Liver Disease · doi:10.1055/a-2601-9426 · Cited by 1
Metadata
- Authors
- Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., Invernizzi, P., Jones, D., Kruger, F. C., Lawitz, E., Mayo, M. J., Shiffman, M. L., Swain, M. G., Valera, J. M., Vargas, V., Vierling, J. M., Villamil, A., Addy, C., Dietrich, J., Germain, J.-M., Mazain, S., Rafailovic, D., Taddé, B., Miller, B., Shu, J., Zein, C. O., & Schattenberg, J. M.
- Affiliations
- Universidade Federal do Rio Grande (BR)
- From Liver Institute Northwest, Seattle (K.V.K.); the Division of Gastroenterology and Hepatology, UC Davis School of Medicine, Sacramento (C.L.B.); Schiff Center for Liver Diseases, University of Miami, Miami (C.L.); the Department of Gastroenterology, Ege University Faculty of Medicine, İzmir, Turkey (U.S.A.); Gastroenterology and Hepatology Division, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (M.R.A.-S.); Medicina Interna Metabolica, Baggiovara Hospital, Azienda Ospedaliero-Universitaria di Modena and Università di Modena e Reggio Emilia, Modena (P.A.), and the Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, and the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori, Monza (P.I.) — all in Italy; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago ...
- ORCID
- Kowdley, Kris V.
- Bowlus, Christopher L.
- Levy, Cynthia
- Akarca, Ulus S.
- Arrese, Marco
- Corpechot, Christophe
- Francque, Sven M.
- Heneghan, Michael A.
- Invernizzi, Pietro
- Jones, David
- Lawitz, Eric
- Mayo, Marlyn J.
- Shiffman, Mitchell L.
- Swain, Mark G.
- Vierling, John M.
- Villamil, Alejandra
- Addy, Carol
- Dietrich, Julie
- Rafailovic, Dragutin
- Schattenberg, Jörn M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-29
- Volume
- 390
- Issue
- 9
- Pages
- 795-805
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388621682
- Semantic Scholar
- 737ff94dc0523a82fdfc3a80f921364b42703d37
- Cited by
- 314
- References
- 33
- Citations by year
- 2026: 112 · 2025: 125 · 2024: 76
- FWCI
- 52.53
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Ipsen
- GENFIT
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- elafibranor, primary biliary cirrhosis, ursodeoxycholic acid, cholestasis, alkaline phosphatase, pruritus, liver fibrosis, treatment efficacy, drug safety, bile duct destruction, cholestatic liver disease
- MeSH terms
- Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Cholestasis, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Propionates, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, Chalcones, Peroxisome Proliferator-Activated Receptors, PPAR alpha, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.